Sivextro (tedizolid) / Merck (MSD), Nabriva Therap - LARVOL DELTA

Between a Heart and a Hard Node: A Difficult Case of Lymphadenopathy (ISHLT 2026) - "For immunosuppression, he was on belatacept, tacrolimus, mycophenolate, and prednisone...He was started on empiric mycobacterial treatment with intravenous amikacin, imipenem, linezolid, ethambutol, and rifabutin...He completed 4 weeks of ertapenem, and has continued on isavuconazole, azithromycin, ethambutol, rifabutin, and tedizolid.Summary This case highlights a challenging presentation of lymphadenopathy with B-symptoms initially concerning for PTLD but was found to have multiple infections. In immunosuppressed patients, overlapping infectious and noninfectious processes can complicate diagnosis. Obtaining comprehensive diagnostic evaluation is essential to identify the cause and initiate appropriate therapy for optimal outcomes."

Clinical • Cardiomyopathy • Cardiovascular • Infectious Disease • Pneumonia

New Lungs, Old Foes: The Challenges of Resistant Infections Pre - and Post-Transplant in a Patient with Cystic Fibrosis (ISHLT 2026) - "The patient was initiated on intravenous (IV) imipenem-cilastatin-relebactam and IV colistin based on clinical improvement with this regimen during a prior exacerbation...Sputum cultures grew methicillin-susceptible Staphylococcus aureus and P. aeruginosa susceptible to cefiderocol...He was started on empiric therapy for rapid growing NTM infection with tedizolid, azithromycin, ethambutol, imipenem, moxifloxacin, and inhaled amikacin...Following availability of susceptibilities, the patient was discharged on IV amikacin, oral azithromycin, and oral omadacycline. Donor investigation revealed a healthy 19-year-old man who drowned in a chlorinated pool.Summary This case highlights a successful lung transplant in a CF patient with ongoing pan-drug-resistant Pseudomonas infection, complicated by a donor-derived polymicrobial NTM infection. Although rare, such infections can be effectively managed with thoughtfully selected antimicrobial therapy."

Clinical • Post-transplantation • Bronchiectasis • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Transplantation

Advances in Therapeutic Drug Monitoring and Pharmacokinetic Researches of Oxazolidinone Antibacterial Agents in the Elderly Patients. (PubMed, Clin Interv Aging) - "Therefore, this article comprehensively reviews the progress in therapeutic drug monitoring (TDM) and pharmacokinetic (PK) studies of linezolid, contezolid and tedizolid in the elderly population, to inform individualized dosing strategies...The PK characteristics of oxazolidinone antibiotics may be altered in the elderly population. TDM and model-informed precision dosing (MIPD) are crucial approaches for achieving individualized dosing strategies."

Journal • PK/PD data • Review • Infectious Disease

Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial (clinicaltrialsregister.eu) - P4 | N=456 | Not yet recruiting | Sponsor: Assistance Publique Hopitaux De Paris

Head-to-Head • New P4 trial • Hepatology

[Translated article] Multidrug-resistant extra-pulmonary tuberculosis in a hemodialysis patient treated with bedaquiline and tedizolid. A case report and a literature review. (PubMed, Farm Hosp) - No abstract available

Journal • Infectious Disease • Pulmonary Disease • Renal Disease • Respiratory Diseases • Tuberculosis

In vitro activity of recently introduced Gram-positive-specific antimicrobial agents against Australian methicillin-resistant Staphylococcus aureus isolates. (PubMed, Pathology) - "MIC was determined for ceftaroline, ceftobiprole, tedizolid, dalbavancin, eravacycline, omadacycline, delafloxacin, lefamulin and vancomycin. Susceptibility testing prior to use of delafloxacin, lefamulin and omadacycline should be considered. When the use of these agents becomes commonplace, ongoing monitoring for resistance is recommended."

Journal • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases

Rifamycin-, macrolide-, and ethambutol-free combinations to treat Mycobacterium avium complex lung disease. (PubMed, Int J Tuberc Lung Dis) - "OBJECTIVEPoor sustained sputum culture conversion with guidelines-based therapy for Mycobacterium avium complex lung disease highlights the need for new and improved multidrug combinations.DESIGNWe tested eight drugs by performing minimum inhibitory concentration (MIC) experiments with the ATCC#700898 strain and 49 clinical isolates, followed by single and multidrug combination studies.RESULTSMIC90 of rifabutin, rifampin, azithromycin, and ethambutol were 4, 16, 256, and 128 mg/L, respectively. The tebipenem-tedizolid-minocycline combination killed 4.82 ± 0.42 log10 CFU/mL; however, addition of bedaquiline resulted in a lower kill of 2.71 ± 0.22 log10 CFU/mL, suggesting a likely antagonism.CONCLUSIONWe tested eight different drugs to identify several rifamycin-, macrolide-, and ethambutol-free oral multidrug combinations. The minocycline-based regimens warrant further preclinical and clinical testing.."

Journal • Pulmonary Disease • Respiratory Diseases

Structural modification of oxazolidinone antibiotics alters nascent peptide stalling preference and peptide trajectory through the ribosome. (PubMed, bioRxiv) - "Delpazolid, which shares the C5 hydroxymethyl moiety with tedizolid, shows a similar preference. Structural analysis of the ribosome with tedizolid and a stalled nascent peptide showed a compacted, helical conformation of the nascent chain induced by the drug. Our findings reveal that stalling preferences of oxazolidinones can be modulated by structural modifications within this antibiotic class."

Journal

Molecular basis of linezolid resistance in Finegoldia spp. from orthopedic infections. (PubMed, Antimicrob Agents Chemother) - "isolates, particularly in polymicrobial infections, when LZD is considered for the treatment. If LZD is ineffective, tedizolid testing may be suggested as a potential therapeutic alternative."

Journal • Infectious Disease • Musculoskeletal Diseases • Orthopedics

Preserving the Antimycobacterial Drug Arsenal: A Case Report of Disseminated Mycobacterium Avium Disease (IWLH 2026) - "The patient was treated with clarithromycin, ethambutol, rifabutin, moxifloxacin, and cycloserine for two years, with amikacin added for the first six months, inducing ototoxicity...A salvage regimen was initiated, including amikacin, tedizolid, clofazimine, ceftazidime/avibactam, isoniazid, delamanide, and ethambutol, as well as antiepileptic treatment and IFNγ administration...Intravenous dexamethasone was administered with intensified NTM treatment, but blood cell counts continued to decline, and inflammatory markers (CRP, PCT) remained high. Due to previous Gram-negative infections, his regimen was modified to include daptomycin, meropenem/vaborbactam, and colistimethate. Candida glabrata was identified in port cultures, necessitating port removal and initiation of isavuconazole. He was placed on dual beta-lactam therapy (meropenem and ceftriaxone) combined with clofazimine, isoniazid, linezolid, cycloserine, bedaquiline, and pretomanid...Conclusions This case..."

Case report • Clinical • CNS Disorders • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pulmonary Disease • Respiratory Diseases • Septic Shock • IFNG • IL12A

Proportion and antibiogram of methicillin-resistant Staphylococcus aureus (MRSA) in Africa: a systematic review and meta-analysis. (PubMed, Antimicrob Resist Infect Control) - "The proportion of MRSA in Africa remains high at 42.2%, with marked regional disparities. Although resistance rates for linezolid and vancomycin are relatively low, they surpass global averages, raising concerns about emerging resistance. Alarmingly high resistance rates to several other antibiotics further underscore the urgent need for targeted interventions and continuous surveillance."

Journal • Retrospective data • Infectious Disease

Optimizing Tedizolid Dosing in Cerebral Nocardiosis: Clinical Impact of Direct Unbound Concentration Measurement and Population PK Modelling in Two Cases. (PubMed, JAC Antimicrob Resist) - "Although higher dosing may improve central nervous system (CNS) exposure and outcomes, tedizolid should not be considered interchangeable with linezolid for CNS nocardiosis. Individualized monitoring of free plasma levels may help optimize dosing strategies."

Journal • CNS Disorders • Dermatology • Diabetes • Hematological Disorders • Infectious Disease • Metabolic Disorders • CD4

Pharmacodynamic evidence for tedizolid use in Mycobacterium avium lung disease. (PubMed, IJTLD Open) - "Based on the reported HFS-MAC studies using multiple clinical isolates of MAC, we propose that tedizolid at 200-300 mg/day should be tested as the backbone of novel combinations to treat MAC-LD."

Journal • PK/PD data • Pulmonary Disease • Respiratory Diseases

Health Technology Assessment of Oxazolidinones for MRSA-Associated Complicated Skin and Soft Tissue Infections. (PubMed, Drug Des Devel Ther) - "The ranking was primarily driven by tedizolid's once-daily dosing and lowest total course cost, linezolid's pediatric indication and widespread availability, and contezolid's superior safety profile, although its overall score was limited by higher cost and lack of guideline recommendations. This study recommends the selection of tedizolid, linezolid, and contezolid for use in medical institutions during the introduction and application of oxazolidinone antibiotics."

Journal • Infectious Disease • Pediatrics

Subinhibitory concentrations of tedizolid induce upregulation of virulence gene transcription in Staphylococcus aureus. (PubMed, J Infect Dev Ctries) - "Sub-MIC of tedizolid and linezolid could increase the mRNA levels of different types of virulence genes in S. aureus, with strain-dependent variations. These findings provide new insights into the potential role of oxazolidinones in bacterial virulence regulation."

Journal

Antibiotic dose-response curves can measure antibiotic activity against Mycobacterium abscessus and Mycobacterium peregrinum. (PubMed, bioRxiv) - "We used Clinical and Laboratory Standards Institute growth conditions for rapid-grower nontuberculous mycobacteria to generate 990 dose-response curves across three time points (72 hours, 96 hours, and 120 hours) for six guideline-recommended (clarithromycin, amikacin, cefoxitin, linezolid, tigecycline, and clofazimine) and five new (omadacycline, tedizolid, SPR719, SQ109, and bedaquiline) antibiotics against Mycobacterium abscessus subspecies abscessus ATCC 19977 and Mycobacterium peregrinum ATCC 700686. We identified time-dependent changes in dose-response curve metrics that allow the detection of inducible clarithromycin resistance with only five days of incubation. This study demonstrates the potential of dose-response curves in measuring antibiotic activity against Mycobacterium abscessus ."

Journal • Nontuberculous Mycobacterial Disease • Respiratory Diseases

Sodium load of novel antibiotics: considerations for nephrologists and clinicians. (PubMed, Int Urol Nephrol) - "Parenteral antibiotics are an often-overlooked contributor to sodium intake. Clinicians should be aware of this hidden source in sodium-sensitive patients such as kidney disease patients. We propose a visual chart to support sodium-conscious antimicrobial selection as part of broader stewardship strategies."

Journal • Review • Chronic Kidney Disease • Nephrology • Renal Disease

A Persistent Problem: Mycobacterium abscessus Infection of an Orthopedic Device after Trauma. (PubMed, Mil Med) - "After a multitude of surgeries, including orthopedic hardware removal from the forearm, and concurrent antibiotic therapy of amikacin, imipenem, tedizolid, and omadacycline, the patient was deemed medically cleared of her infection. This has implications for both civilian and military battlefield-related trauma infections. This case serves as an example of successful multi-disciplinary management through appropriately aggressive surgery and tailored antibiotic therapy."

Journal • Infectious Disease • Musculoskeletal Diseases • Nontuberculous Mycobacterial Disease • Orthopedics

Hybrid Antibiotics Targeting the Bacterial Ribosome. (PubMed, ACS Cent Sci) - "Here we describe the design, synthesis, and microbiological and structural characterization of hybrid antibiotics of azithromycin, tedizolid, and chloramphenicol that span the peptidyltransferase center (PTC) and nascent peptide exit tunnel (NPET) in the bacterial ribosome. These results extend our understanding of ribosome inhibition and provide a pipeline for the rational design of dual-action antibiotics that target the ribosome. In a broader context, this work offers a framework for developing bifunctional inhibitors that engage adjacent binding sites by means of a rational cycle of synthetic optimization, biological evaluation, and structural characterization."

Journal • Infectious Disease

How to use novel antimicrobials beyond official indications: an expert consensus. (PubMed, JAC Antimicrob Resist) - "The process comprised three survey rounds evaluating off-label uses of eight drugs: ceftazidime-avibactam, ceftolozane-tazobactam, cefiderocol, ceftaroline, ceftobiprole, dalbavancin, tedizolid, and isavuconazole. The guidance prioritizes targeted treatment over empirical use, aligning with international ASP principles and WHO recommendations. These results provide a regional reference to optimize ASP initiatives focus on new antibiotic use while minimizing ecological impact and resistance development."

Journal • Cardiovascular • Critical care • Infectious Disease

Multidrug-resistant extra-pulmonary tuberculosis in a hemodyalisis patient treated with bedaquiline and tedizolid. A case report and a literature rewiew. (PubMed, Farm Hosp) - No abstract available

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

In Vitro Activity of Sulfamethoxazole-Trimethoprim, Amikacin, Oxazolidinones, Fluoroquinolones and Fidaxomicin against Isolates of Nocardia. (PubMed, ACS Omega) - "This study evaluates the in vitro activity of common and potential antimicrobials, including Trimethoprim-sulfamethoxazole, Amikacin, Oxazolidinones (Linezolid, Tedizolid, Contezolid), Fluoroquinolones (Moxifloxacin, Levofloxacin, Sitafloxacin), Rifampicin, and Fidaxomicin against 51 clinical Nocardia isolates. These findings highlight the need for tailored treatment strategies based on species-specific susceptibility and resistance profiles and suggest Fidaxomicin and Sitafloxacin as promising options. Further clinical validation is warranted to optimize therapeutic outcomes."

Journal • Preclinical • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Therapeutic options and prognostic risk factors in diabetic foot osteomyelitis: a narrative review. (PubMed, Int J Surg) - "Emerging antimicrobial agents such as dalbavancin, tedizolid, and novel cephalosporins, alongside bacteriophage therapy and immunomodulatory strategies like granulocyte colony-stimulating factor (G-CSF), show promise in improving infection management. Prognosis heavily depends on glycemic control, renal function, immune status, and cardiovascular health. Comprehensive multidisciplinary management is crucial to improving patient outcomes, reducing amputations, and enhancing quality of life."

Journal • Cardiovascular • Diabetes • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics

Anti-IFN-gamma Autoantibodies In An Adult Patient With Disseminated Mycobacterium Abscessus Infection (ACAAI 2025) - "Supraclavicular lymph node biopsy showed inflammation with sclerosis, and cultures grew M. abscessus , prompting initiation of amikacin, meropenem, and omadacycline. Seven months later, patient had radiographic and clinical improvement and was transitioned to oral omadacycline and tedizolid for minimum twelve-month course...Identification of anti-IFN-γ autoantibodies is critical given the role of immunomodulatory therapies including rituximab and IFN-γ in patients with antimicrobial-refractory infections. Most recently, CAAR T cell therapy has shown promise in averting anti-IFN-γ autoantibody-related infections by targeting self-reactive B cells."

Clinical • Asthma • Cough • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Influenza • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Tetanus • Tuberculosis • CD4 • CSF2 • IFNG

Omadacycline for the treatment of acute bacterial skin and skin structure infections: a systematic review and network meta-analysis. (PubMed, BMC Infect Dis) - "Our findings indicate that omadacycline is a promising treatment option for ABSSSI, demonstrating efficacy that is comparable to or potentially superior to many other anti-MRSA agents, along with a favorable safety profile. However, these results should be interpreted with caution due to the study's inherent limitations."

Clinical • Journal • Retrospective data • Review • Infectious Disease